 | • レポートコード：GIR-2104Z09923 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、神経保護薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経保護薬の種類別市場規模（コリンエステラーゼ阻害剤、抗炎症剤、その他）、用途別市場規模（アルツハイマー病、パーキンソン病、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・神経保護薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Genervon、NeuroVive Pharmaceutical、Ceregene、BHR Pharma、Neuren Pharmaceuticals、Allon therapeutics、Bionure ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：コリンエステラーゼ阻害剤、抗炎症剤、その他 ・用途別分析2016年-2026年：アルツハイマー病、パーキンソン病、その他 ・神経保護薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・神経保護薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・神経保護薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・神経保護薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・神経保護薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Neuroprotective Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Neuroprotective Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Neuroprotective Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Neuroprotective Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Cholinesterase inhibitors
Anti-inflammatory
Others
Market segment by Application can be divided into
Alzheimer’s disease
Parkinson’s disease
Others
The key market players for global Neuroprotective Drugs market are listed below:
Genervon
NeuroVive Pharmaceutical
Ceregene
BHR Pharma
Neuren Pharmaceuticals
Allon therapeutics
Bionure
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Neuroprotective Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroprotective Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Cholinesterase inhibitors
1.2.3 Anti-inflammatory
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroprotective Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Alzheimer’s disease
1.3.3 Parkinson’s disease
1.3.4 Others
1.4 Global Neuroprotective Drugs Market Size & Forecast
1.4.1 Global Neuroprotective Drugs Sales in Value (2016-2026))
1.4.2 Global Neuroprotective Drugs Sales in Volume (2016-2026)
1.4.3 Global Neuroprotective Drugs Price by Type (2016-2026) & (USD/Kg)
1.5 Global Neuroprotective Drugs Production Capacity Analysis
1.5.1 Global Neuroprotective Drugs Total Production Capacity (2016-2026)
1.5.2 Global Neuroprotective Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroprotective Drugs Market Drivers
1.6.2 Neuroprotective Drugs Market Restraints
1.6.3 Neuroprotective Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Genervon
2.1.1 Genervon Details
2.1.2 Genervon Major Business
2.1.3 Genervon Neuroprotective Drugs Product and Services
2.1.4 Genervon Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 NeuroVive Pharmaceutical
2.2.1 NeuroVive Pharmaceutical Details
2.2.2 NeuroVive Pharmaceutical Major Business
2.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Product and Services
2.2.4 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Ceregene
2.3.1 Ceregene Details
2.3.2 Ceregene Major Business
2.3.3 Ceregene Neuroprotective Drugs Product and Services
2.3.4 Ceregene Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 BHR Pharma
2.4.1 BHR Pharma Details
2.4.2 BHR Pharma Major Business
2.4.3 BHR Pharma Neuroprotective Drugs Product and Services
2.4.4 BHR Pharma Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Neuren Pharmaceuticals
2.5.1 Neuren Pharmaceuticals Details
2.5.2 Neuren Pharmaceuticals Major Business
2.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Product and Services
2.5.4 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Allon therapeutics
2.6.1 Allon therapeutics Details
2.6.2 Allon therapeutics Major Business
2.6.3 Allon therapeutics Neuroprotective Drugs Product and Services
2.6.4 Allon therapeutics Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Bionure
2.7.1 Bionure Details
2.7.2 Bionure Major Business
2.7.3 Bionure Neuroprotective Drugs Product and Services
2.7.4 Bionure Neuroprotective Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Neuroprotective Drugs Sales by Manufacturer
3.1 Global Neuroprotective Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Neuroprotective Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Neuroprotective Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neuroprotective Drugs Manufacturer Market Share
3.4.2 Top 6 Neuroprotective Drugs Manufacturer Market Share
3.5 Global Neuroprotective Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Neuroprotective Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neuroprotective Drugs Market Size by Region
4.1.1 Global Neuroprotective Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Neuroprotective Drugs Revenue by Region (2016-2026)
4.2 North America Neuroprotective Drugs Revenue (2016-2026)
4.3 Europe Neuroprotective Drugs Revenue (2016-2026)
4.4 Asia-Pacific Neuroprotective Drugs Revenue (2016-2026)
4.5 South America Neuroprotective Drugs Revenue (2016-2026)
4.6 Middle East and Africa Neuroprotective Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Neuroprotective Drugs Sales in Volume by Type (2016-2026)
5.2 Global Neuroprotective Drugs Revenue by Type (2016-2026)
5.3 Global Neuroprotective Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Neuroprotective Drugs Sales in Volume by Application (2016-2026)
6.2 Global Neuroprotective Drugs Revenue by Application (2016-2026)
6.3 Global Neuroprotective Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Neuroprotective Drugs Sales by Type (2016-2026)
7.2 North America Neuroprotective Drugs Sales by Application (2016-2026)
7.3 North America Neuroprotective Drugs Market Size by Country
7.3.1 North America Neuroprotective Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Neuroprotective Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Neuroprotective Drugs Sales by Type (2016-2026)
8.2 Europe Neuroprotective Drugs Sales by Application (2016-2026)
8.3 Europe Neuroprotective Drugs Market Size by Country
8.3.1 Europe Neuroprotective Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Neuroprotective Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Neuroprotective Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Neuroprotective Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Neuroprotective Drugs Market Size by Region
9.3.1 Asia-Pacific Neuroprotective Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Neuroprotective Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Neuroprotective Drugs Sales by Type (2016-2026)
10.2 South America Neuroprotective Drugs Sales by Application (2016-2026)
10.3 South America Neuroprotective Drugs Market Size by Country
10.3.1 South America Neuroprotective Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Neuroprotective Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neuroprotective Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Neuroprotective Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Neuroprotective Drugs Market Size by Country
11.3.1 Middle East & Africa Neuroprotective Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Neuroprotective Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Neuroprotective Drugs Typical Distributors
12.3 Neuroprotective Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Neuroprotective Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Neuroprotective Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Genervon Basic Information, Manufacturing Base and Competitors
Table 4. Genervon Major Business
Table 5. Genervon Neuroprotective Drugs Product and Services
Table 6. Genervon Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. NeuroVive Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 8. NeuroVive Pharmaceutical Major Business
Table 9. NeuroVive Pharmaceutical Neuroprotective Drugs Product and Services
Table 10. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Ceregene Basic Information, Manufacturing Base and Competitors
Table 12. Ceregene Major Business
Table 13. Ceregene Neuroprotective Drugs Product and Services
Table 14. Ceregene Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. BHR Pharma Basic Information, Manufacturing Base and Competitors
Table 16. BHR Pharma Major Business
Table 17. BHR Pharma Neuroprotective Drugs Product and Services
Table 18. BHR Pharma Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Neuren Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. Neuren Pharmaceuticals Major Business
Table 21. Neuren Pharmaceuticals Neuroprotective Drugs Product and Services
Table 22. Neuren Pharmaceuticals Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Allon therapeutics Basic Information, Manufacturing Base and Competitors
Table 24. Allon therapeutics Major Business
Table 25. Allon therapeutics Neuroprotective Drugs Product and Services
Table 26. Allon therapeutics Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Bionure Basic Information, Manufacturing Base and Competitors
Table 28. Bionure Major Business
Table 29. Bionure Neuroprotective Drugs Product and Services
Table 30. Bionure Neuroprotective Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Global Neuroprotective Drugs Sales by Manufacturer (2019-2021e) & (MT)
Table 32. Global Neuroprotective Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 33. Market Position of Manufacturers in Neuroprotective Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 34. Global Neuroprotective Drugs Production Capacity by Company, (MT): 2020 VS 2021
Table 35. Head Office and Neuroprotective Drugs Production Site of Key Manufacturer
Table 36. Global Neuroprotective Drugs Sales by Region (2016-2021e) & (MT)
Table 37. Global Neuroprotective Drugs Sales by Region (2021-2026) & (MT)
Table 38. Global Neuroprotective Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 39. Global Neuroprotective Drugs Revenue by Region (2021-2026) & (USD Million)
Table 40. Global Neuroprotective Drugs Sales by Type (2016-2021e) & (MT)
Table 41. Global Neuroprotective Drugs Sales by Type (2021-2026) & (MT)
Table 42. Global Neuroprotective Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 43. Global Neuroprotective Drugs Revenue by Type (2021-2026) & (USD Million)
Table 44. Global Neuroprotective Drugs Price by Type (2016-2021e) & (USD/Kg)
Table 45. Global Neuroprotective Drugs Price by Type (2021-2026) & (USD/Kg)
Table 46. Global Neuroprotective Drugs Sales by Application (2016-2021e) & (MT)
Table 47. Global Neuroprotective Drugs Sales by Application (2021-2026) & (MT)
Table 48. Global Neuroprotective Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 49. Global Neuroprotective Drugs Revenue by Application (2021-2026) & (USD Million)
Table 50. Global Neuroprotective Drugs Price by Application (2016-2021e) & (USD/Kg)
Table 51. Global Neuroprotective Drugs Price by Application (2021-2026) & (USD/Kg)
Table 52. North America Neuroprotective Drugs Sales by Country (2016-2021e) & (MT)
Table 53. North America Neuroprotective Drugs Sales by Country (2021-2026) & (MT)
Table 54. North America Neuroprotective Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 55. North America Neuroprotective Drugs Revenue by Country (2021-2026) & (USD Million)
Table 56. North America Neuroprotective Drugs Sales by Type (2016-2021e) & (MT)
Table 57. North America Neuroprotective Drugs Sales by Type (2021-2026) & (MT)
Table 58. North America Neuroprotective Drugs Sales by Application (2016-2021e) & (MT)
Table 59. North America Neuroprotective Drugs Sales by Application (2021-2026) & (MT)
Table 60. Europe Neuroprotective Drugs Sales by Country (2016-2021e) & (MT)
Table 61. Europe Neuroprotective Drugs Sales by Country (2021-2026) & (MT)
Table 62. Europe Neuroprotective Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 63. Europe Neuroprotective Drugs Revenue by Country (2021-2026) & (USD Million)
Table 64. Europe Neuroprotective Drugs Sales by Type (2016-2021e) & (MT)
Table 65. Europe Neuroprotective Drugs Sales by Type (2021-2026) & (MT)
Table 66. Europe Neuroprotective Drugs Sales by Application (2016-2021e) & (MT)
Table 67. Europe Neuroprotective Drugs Sales by Application (2021-2026) & (MT)
Table 68. Asia-Pacific Neuroprotective Drugs Sales by Region (2016-2021e) & (MT)
Table 69. Asia-Pacific Neuroprotective Drugs Sales by Region (2021-2026) & (MT)
Table 70. Asia-Pacific Neuroprotective Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 71. Asia-Pacific Neuroprotective Drugs Revenue by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Neuroprotective Drugs Sales by Type (2016-2021e) & (MT)
Table 73. Asia-Pacific Neuroprotective Drugs Sales by Type (2021-2026) & (MT)
Table 74. Asia-Pacific Neuroprotective Drugs Sales by Application (2016-2021e) & (MT)
Table 75. Asia-Pacific Neuroprotective Drugs Sales by Application (2021-2026) & (MT)
Table 76. South America Neuroprotective Drugs Sales by Country (2016-2021e) & (MT)
Table 77. South America Neuroprotective Drugs Sales by Country (2021-2026) & (MT)
Table 78. South America Neuroprotective Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 79. South America Neuroprotective Drugs Revenue by Country (2021-2026) & (USD Million)
Table 80. South America Neuroprotective Drugs Sales by Type (2016-2021e) & (MT)
Table 81. South America Neuroprotective Drugs Sales by Type (2021-2026) & (MT)
Table 82. South America Neuroprotective Drugs Sales by Application (2016-2021e) & (MT)
Table 83. South America Neuroprotective Drugs Sales by Application (2021-2026) & (MT)
Table 84. Middle East & Africa Neuroprotective Drugs Sales by Country (2016-2021e) & (MT)
Table 85. Middle East & Africa Neuroprotective Drugs Sales by Country (2021-2026) & (MT)
Table 86. Middle East & Africa Neuroprotective Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 87. Middle East & Africa Neuroprotective Drugs Revenue by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Neuroprotective Drugs Sales by Type (2016-2021e) & (MT)
Table 89. Middle East & Africa Neuroprotective Drugs Sales by Type (2021-2026) & (MT)
Table 90. Middle East & Africa Neuroprotective Drugs Sales by Application (2016-2021e) & (MT)
Table 91. Middle East & Africa Neuroprotective Drugs Sales by Application (2021-2026) & (MT)
Table 92. Direct Channel Pros & Cons
Table 93. Indirect Channel Pros & Cons
Table 94. Neuroprotective Drugs Typical Distributors
Table 95. Neuroprotective Drugs Typical Customers
List of Figures
Figure 1. Neuroprotective Drugs Picture
Figure 2. Global Neuroprotective Drugs Sales Market Share by Type in 2020
Figure 3. Cholinesterase inhibitors
Figure 4. Anti-inflammatory
Figure 5. Others
Figure 6. Global Neuroprotective Drugs Sales Market Share by Application in 2020
Figure 7. Alzheimer's disease
Figure 8. Parkinson's disease
Figure 9. Others
Figure 10. Global Neuroprotective Drugs Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 11. Global Neuroprotective Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. United States Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Canada Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Mexico Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Germany Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. France Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. United Kingdom Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Russia Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Italy Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. China Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Japan Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Korea Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. India Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Southeast Asia Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Australia Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Brazil Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Egypt Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Saudi Arabia Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. South Africa Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Turkey Neuroprotective Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Global Neuroprotective Drugs Sales (2016-2026) & (MT)
Figure 32. Global Neuroprotective Drugs Production Capacity (2016-2026) & (MT)
Figure 33. Global Neuroprotective Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 34. Neuroprotective Drugs Market Drivers
Figure 35. Neuroprotective Drugs Market Restraints
Figure 36. Neuroprotective Drugs Market Trends
Figure 37. Global Neuroprotective Drugs Sales Market Share by Manufacturer in 2020
Figure 38. Global Neuroprotective Drugs Revenue Market Share by Manufacturer in 2020
Figure 39. Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 40. Top 3 Neuroprotective Drugs Manufacturer (Revenue) Market Share in 2020
Figure 41. Top 6 Neuroprotective Drugs Manufacturer (Revenue) Market Share in 2020
Figure 42. Global Neuroprotective Drugs Sales Market Share by Region (2016-2026)
Figure 43. Global Neuroprotective Drugs Revenue Market Share by Region (2016-2026)
Figure 44. North America Neuroprotective Drugs Revenue (2016-2026) & (USD Million)
Figure 45. Europe Neuroprotective Drugs Revenue (2016-2026) & (USD Million)
Figure 46. Asia-Pacific Neuroprotective Drugs Revenue (2016-2026) & (USD Million)
Figure 47. South America Neuroprotective Drugs Revenue (2016-2026) & (USD Million)
Figure 48. Middle East & Africa Neuroprotective Drugs Revenue (2016-2026) & (USD Million)
Figure 49. Global Neuroprotective Drugs Sales Market Share by Type (2016-2026)
Figure 50. Global Neuroprotective Drugs Revenue Market Share by Type (2016-2026)
Figure 51. Global Neuroprotective Drugs Price by Type (2016-2026) & (USD/Kg)
Figure 52. Global Neuroprotective Drugs Sales Market Share by Application (2016-2026)
Figure 53. Global Neuroprotective Drugs Revenue Market Share by Application (2016-2026)
Figure 54. Global Neuroprotective Drugs Price by Application (2016-2026) & (USD/Kg)
Figure 55. North America Neuroprotective Drugs Sales Market Share by Country (2016-2026)
Figure 56. North America Neuroprotective Drugs Revenue Market Share by Country (2016-2026)
Figure 57. North America Neuroprotective Drugs Sales Market Share by Type (2016-2026)
Figure 58. North America Neuroprotective Drugs Sales Market Share by Application (2016-2026)
Figure 59. Europe Neuroprotective Drugs Sales Market Share by Country (2016-2026)
Figure 60. Europe Neuroprotective Drugs Revenue Market Share by Country (2016-2026)
Figure 61. Europe Neuroprotective Drugs Sales Market Share by Type (2016-2026)
Figure 62. Europe Neuroprotective Drugs Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Neuroprotective Drugs Sales Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Neuroprotective Drugs Revenue Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Neuroprotective Drugs Sales Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Neuroprotective Drugs Sales Market Share by Application (2016-2026)
Figure 67. South America Neuroprotective Drugs Sales Market Share by Country (2016-2026)
Figure 68. South America Neuroprotective Drugs Revenue Market Share by Country (2016-2026)
Figure 69. South America Neuroprotective Drugs Sales Market Share by Type (2016-2026)
Figure 70. South America Neuroprotective Drugs Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Neuroprotective Drugs Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Neuroprotective Drugs Revenue Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Neuroprotective Drugs Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Neuroprotective Drugs Sales Market Share by Application (2016-2026)
Figure 75. Sales Channel: Direct Channel vs Indirect Channel
Figure 76. Methodology
Figure 77. Research Process and Data Source
世界の髄膜炎菌性疾患治療薬市場 2021：企業別、地域別、種類・用途別 The Meningococcal Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…- 世界のアルツハイマー病治療薬市場 2021：企業別、地域別、種類・用途別 The Alzheimer’s Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, …
- 世界のアンチエイジング薬市場 2021：企業別、地域別、種類・用途別 The Anti-Ageing Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, …
- 世界の抗喘息薬市場 2021：企業別、地域別、種類・用途別 The Anti Asthma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, …
- 世界の抗てんかん薬市場 2021：企業別、地域別、種類・用途別 The Anti Epilepsy Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…